Halberd Corporation2020-09-14T13:05:54-04:00

Moving Forward

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

COVID-19

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

PTSD

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Chronic Traumatic Encephalopathy

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Cancer

Halberd Corporation (HALB) patented extracorporeal treatment is applicable to many hard-to-cure blood-borne and neurologic diseases, including Covid-19, other viruses, PTSD, cancer, etc.

Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus’. The issued patents’ extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others.

We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.

Halberd Corporation Fact Sheet

A brief review of some of Halberd’s significant accomplishments and recent developments.

PROPRIETARY SEQUENTIAL DIALYSIS TECHNIQUE

A methodology that physically removes the pathophysiologic basis of the disease

The Company’s proprietary Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without dangerous side effects.

  • Superior to current treatments which eliminate the presence of most illnesses but often with catastrophic or even fatal side effects.
  • Subtractive therapy (removal of harmful molecules) reduces risks associated with conventional “Additive” therapy (adding chemicals to the body).
  • Targets Covid-19 and similar viral diseases initially, with future efforts to develop treatments for Alzheimer’s Disease, PTSD/Traumatic Brain Injury, and cancer.
View all patents

Halberd News

Press releases and updates on our medical breakthroughs.

Halberd Corp. Designated as a BREAKOUT Stock to Watch in Investor Publications

Jackson Center, PA, May 10, 2021 – Halberd Corporation (OTC-PINK: "HALB") was recently discussed in Penny Stocks News and Wall Street Trader publications as a BREAKOUT stock to watch with a projected share price of HALB to rise above the $0.06/share level. Halberd Corporation did not participate in these determinations, nor does ...

Halberd Corporation Appoints New Chief Technical Officer to Optimize Upcoming Experiments On Radio Frequency and Laser Eradication of Disease

Jackson Center, PA, May 4, 2021 – Halberd Corporation (OTC-PINK: "HALB") announces the appointment of Dr. Mitchell S. Felder, previously a consultant to Halberd Corporation, to the position of Chief Technical Officer.  Dr. Patricio Reyes, former Chief Technical Officer, has requested reduced duties due to pressing other outside commitments, but will continue ...

Halberd Corporation Files International Patent Cooperation Treaty (PCT) Application on Treating and Curing Covid-19 Infection Utilizing a Laser

Jackson Center, PA, April 26, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed an International Patent Cooperation Treaty (PCT) application for coverage of the invention titled, “Treating and Curing Covid-19 Infection Utilizing a Laser.”  The Patent Cooperation Treaty has over 150 participating countries and allows an inventor to seek patent protection in numerous ...

View all news
Go to Top